Balyasny Asset Management
BMY.RT

Balyasny Asset Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Balyasny Asset Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-379,000
Closed -$262K – 2259
2020
Q4 		$262K Buy
+379,000
New +$807K ﹤0.01% 1199
2020
Q2 		– Sell
-67,000
Closed -$255K – 1621
2020
Q1 		$255K Sell
67,000
-433,000
-87% -$1.43M ﹤0.01% 1013
2019
Q4 		$1.5M Buy
+500,000
New +$1.3M 0.01% 809

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Balyasny Asset Management's BMY.RT Position: Q1 2021 in Review

Balyasny Asset Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 379,000 shares — an estimated $262K sold.

Balyasny Asset Management first reported a position in BMY.RT in Q4 2019 and held it in 3 quarters. The position peaked at $1.5M in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Balyasny Asset Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Balyasny Asset Management sold 379,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $262K.
  • Balyasny Asset Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 3 quarters.
  • Balyasny Asset Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.5M in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Balyasny Asset Management's 13F filing for Q1 2021, filed 17 May 2021.